|
A Panoramic View: What Life Scienes Firms Can Learn from Insurance Companies
The Journal of Biolaw & Business
November 2, 2007
|
To really understand the risk profile of a specific biotech, underwriters must take a long-term view of the company and the
exposures associated with different stages of product development.
|
|
An Ounce of Prevention
BioExecutive International
November 2006
|
Developing relationships with first responders can help life sciences companies keep manageable incidents from becoming costly
disasters.
|
|
Critical Coverage
European Pharmaceutical Contractor
Autumn 2006
|
The storage of refrigerated stock is a key exposure faced by most contract manufacturing and research organizations. This
article discusses how to assess and manage this critical risk.
|
|
Global Perspectives on the Life Sciences Industry
Journal of BioLaw & Business
August 2006
|
This article highlights the latest trends and developments in litigation, regulation, risk management and insurance that are
affecting biotech companies worldwide. It includes observations about the insurance needs of biotechnology comapnies in the
United States, Canada, Europe, Australia, Asia and Latin America.
|
|
Contingency Planning: Preparation is the Key to Recovering from Disasters
Journal of BioLaw & Business
June 2006
|
Businesses in any industry can reel from the repercussions of electrical outages, fires, computer hackers or the ravages of
Mother Nature. When such disruptions occur, these companies may be forced to halt operations for days, weeks or even months.
These businesses can and do recover, but in some sectors, like biotechnology, business interruptions that results from such
events are potentially catastrophic. This article provides an overview of practicial items that should be consided by all
life sciences companies as part of contingency planning.
|
|
Risky Business?
European Pharmaceutical Contractor
Autumn 2005
|
This article by Chris Tait discusses the idea that 'risk' is not always as ominous or random as the word suggests. More often
than not, the risks pharmaceutical companies face can be considered, planned for and, in many cases, managed so that business
can flourish.
|
|
Insuring International Clinical Trials: Navigating the Quirks and Avoiding the Quagmires
Journal of BioLaw & Business
July 2005
|
The recent enactment of the European Union (EU) directive on human clinical research illustrates the ever-increasing complexity
of multi-site clinical research. This article discusses the importance of insurance protection against liability in international
clinical trials.
|
|
Will Your Firm Be a Victim of Medical Technology Error & Omissions Litigation
Journal of BioLaw & Business
April 2005
|
This article highlights best risk management practices for companies, with a focus on errors and omissions liability and insurance
protection.
|
